A new radioactive treatment for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male age 18 or older
- You have prostate cancer that has spread and is growing despite hormone therapy
- Your PSMA PET/CT scan must show that your cancer is PSMA-positive (cancer visible on the scan) and no cancer spots that don't show up
- You've already tried at least one hormone pill like enzalutamide or abiraterone, and it stopped working
- You've had at least one (but not more than two) types of chemotherapy (taxane drugs) and it stopped working
- You have good enough organ function (kidney, liver, blood counts) and can care for yourself (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This early-stage trial tests a new radioactive drug (177Lu-FC516) designed to target and treat prostate cancer that has spread and is no longer responding to standard treatments. The goal is to evaluate whether it is safe and effective.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.